Presenter: Martin Åmark, CEO
Market/Indication: Biosimilars based on the patented highly effective technology that contributes to lower productions costs.
Funding Stage: Early Growth, Publicly Listed: Ticker: STO: XBRANE
Development Stage: Phase III
Xbrane Biopharma AB is a biotechnology company which develops and manufactures biosimilars. Xbrane has a patented protein production platform and world-leading expertise within biosimilar development. Xbrane’s headquarter is located in Solna, just outside of Stockholm, and the company has research and development facilities in Sweden and in Italy. Xbrane is listed at Nasdaq Stockholm since September 2019, with the ticker XBRANE.